Leading stakeholders in the effort to combat rare diseases, of which there are as many as 8,000 in Europe, concluded that patients are now beginning to gain improved access to orphan drugs. At the European Health Forum Gastein, a panel of experts reviewed recently established policy measures that the rare disease community has been striving to implement for years, including the development of rare disease national plans. Rare diseases affect up to 30 million people in the EU.